Globeflex Capital L P Buys Shares of 10,963 Medpace Holdings, Inc. $MEDP

Globeflex Capital L P purchased a new position in Medpace Holdings, Inc. (NASDAQ:MEDP) in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor purchased 10,963 shares of the company’s stock, valued at approximately $5,806,000.

A number of other large investors also recently modified their holdings of the business. Johnson Financial Group Inc. acquired a new stake in Medpace in the second quarter worth about $27,000. Geneos Wealth Management Inc. raised its position in shares of Medpace by 64.9% during the 1st quarter. Geneos Wealth Management Inc. now owns 94 shares of the company’s stock worth $29,000 after buying an additional 37 shares in the last quarter. Elyxium Wealth LLC acquired a new stake in shares of Medpace in the 4th quarter worth approximately $30,000. Allied Private Wealth LLC acquired a new stake in shares of Medpace in the 2nd quarter worth approximately $31,000. Finally, Kilter Group LLC bought a new position in shares of Medpace in the second quarter valued at approximately $31,000. 77.98% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

MEDP has been the topic of a number of research analyst reports. Weiss Ratings upgraded shares of Medpace from a “hold (c+)” rating to a “buy (b-)” rating in a research note on Wednesday, August 12th. Truist Financial increased their price target on Medpace from $462.00 to $609.00 and gave the company a “hold” rating in a research note on Friday, July 24th. Robert W. Baird raised their target price on Medpace from $547.00 to $624.00 and gave the company a “neutral” rating in a research note on Friday, July 24th. TD Cowen increased their target price on shares of Medpace from $419.00 to $492.00 and gave the company a “hold” rating in a research note on Friday, July 24th. Finally, Royal Bank Of Canada lifted their price target on shares of Medpace from $484.00 to $692.00 and gave the stock an “outperform” rating in a research report on Friday, July 24th. Three investment analysts have rated the stock with a Buy rating and ten have assigned a Hold rating to the stock. Based on data from MarketBeat.com, Medpace currently has an average rating of “Hold” and a consensus price target of $584.18.

Insider Buying and Selling

In related news, Director Brian T. Carley sold 5,000 shares of the company’s stock in a transaction that occurred on Wednesday, August 19th. The shares were sold at an average price of $608.63, for a total value of $3,043,150.00. Following the completion of the sale, the director owned 27,825 shares in the company, valued at approximately $16,935,129.75. This represents a 15.23% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO August J. Troendle sold 27,174 shares of the company’s stock in a transaction that occurred on Thursday, August 20th. The shares were sold at an average price of $618.79, for a total transaction of $16,814,999.46. Following the completion of the sale, the chief executive officer owned 561,195 shares of the company’s stock, valued at approximately $347,261,854.05. This trade represents a 4.62% decrease in their position. The SEC filing for this sale provides additional information. Over the last 90 days, insiders sold 122,261 shares of company stock valued at $71,729,129. Company insiders own 20.50% of the company’s stock.

Medpace Price Performance

Shares of NASDAQ MEDP opened at $620.75 on Monday. Medpace Holdings, Inc. has a 12 month low of $373.00 and a 12 month high of $677.90. The company has a market cap of $17.33 billion, a price-to-earnings ratio of 36.39, a P/E/G ratio of 2.77 and a beta of 1.15. The business has a fifty day simple moving average of $550.16 and a 200-day simple moving average of $492.03.

Medpace (NASDAQ:MEDP) last issued its quarterly earnings results on Wednesday, July 22nd. The company reported $4.25 earnings per share for the quarter, topping analysts’ consensus estimates of $3.98 by $0.27. The firm had revenue of $707.33 million for the quarter, compared to analysts’ expectations of $689.51 million. Medpace had a return on equity of 110.15% and a net margin of 17.67%.Medpace’s revenue was up 17.2% on a year-over-year basis. During the same quarter last year, the business posted $3.10 EPS. Medpace has set its FY 2026 guidance at 17.250-17.950 EPS. As a group, sell-side analysts expect that Medpace Holdings, Inc. will post 17.54 EPS for the current fiscal year.

Medpace Profile

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.